Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Hopes To Tap AbbVie's ''Humira Magic'' In Immunology Pact

This article was originally published in Scrip

Executive Summary

Boehringer Ingelheim and AbbVie Inc. have launched a global collaboration to develop two of the German group's most advanced biologic compounds in immunology, a therapy field where the US-based group has acquired extensive insight from its TNF inhibitor Humira (adalimumab).

You may also be interested in...



A Virtuous Cycle: What The Immuno-Oncology Revolution Means For Other Disease Areas

Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.

Q&A: AbbVie VP Lin On Filling Humira's Big Shoes In Immunology

AbbVie's Shao-Lee Lin talks about drug candidates that the company hopes will extend its legacy in immunology, which is built on the foundation of the world's top-selling biopharma product Humira.

ACR Roundup: JAK Safety Shown Across Multiple Trials

Low cardiovascular risk was shown in trials presented at the ACR/ARHP annual meeting for Pfizer's, Lilly's and AbbVie's JAK inhibitors in rheumatoid arthritis; AbbVie's Phase II risankizumab results in PsA, biosimilar doubts and more from ACR.

Related Content

Topics

UsernamePublicRestriction

Register

MT125711

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel